🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to researchers.

A Global Health Concern

The sexually transmitted infection are on the rise around the world, with data suggesting more than 82 million new cases annually. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the reality of increasing worldwide cases, the spread of superbugs and the very limited available drugs currently available.”

Public health authorities are deeply concerned about the surge in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, alternatively called Nuzolvence, was cleared by the US FDA in December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This milestone marks a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on findings released by a major medical journal, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which uses two antibiotics. The research included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to make available and distribute the drug in numerous developing nations.

Clinicians treating patients have shared hope. The availability of a one-pill regimen such as this is described as a "game-changer" for public health efforts. This is considered crucial to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea globally.